LCRF is proud to partner with several patient advocacy groups to fund much needed research focusing on specific types of lung cancer.
ALK Positive is committed to raising funds for research that will transform ALK-positive cancer into a chronic or curable condition for all patients living with this disease.
Together, LCRF and ALK Positive are funding three grants totaling $750,000 to advance high-impact research focused upon transforming care and improving outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). 2022 Awardees are:
Jaime Schneider, MD, PhD
Massachusetts General Hospital
Álvaro Villalonga, PhD
Memorial Sloan-Kettering Cancer Center
EGFR Resisters is a grassroots patient-driven community, dedicated exclusively to changing EGFR positive lung cancer into a manageable, chronic disease.
In 2021, LCRF and the EGFR Resisters partnered to fund Dr. Yang Tian, Icahn School of Medicine at Mt. Sinai, and her work on resistance to targeted therapy. Together, LCRF and EGFR Resisters funded three more impactful grants in 2022 in the area of EGFR lung cancer research.
2022 Awardees are:
KRAS Kickers is a non-profit patient founded organization with a mission to connect people to current research, resources, and community to kick cancer’s KRAS. The group empowers patients, brings doctors and researchers with cutting-edge information together in an approachable virtual patient community.
Together, LCRF and KRAS Kickers funded a two-year grant in 2022 with the goal of improving outcomes for people with KRAS-mutant lung cancer. 2022 Awardee is:
MET Crusaders are a community of lung cancer patients, care givers, advocates, researchers, and physicians dedicated to helping patients with the MET alteration live normal lives.
Together, LCRF and MET Crusaders funded three projects in 2022 with the goal of improving outcomes for people with MET-mutant lung cancer.
2022 Awardees are: